CoChat
Sign Up
Cited by 175Vasculitis and related conditionsOtitis Media and Relapsing PolychondritisEosinophilic Disorders and Syndromes

The DOI matches its Crossref record.

Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Cottin, Vincent, Bel, Elisabeth, Bottero, Paolo, Dalhoff, Klaus, Humbert, Marc, Lazor, Romain, Sinico, Renato A., Sivasothy, Pasupathy, Wechsler, Michael E., Groh, Matthieu, Marchand-Adam, Sylvain, Khouatra, Chahéra, Wallaert, Benoit, Taillé, Camille, Delaval, Philippe, Cadranel, Jacques, Bonniaud, Philippe, Prévot, Grégoire, Hirschi, Sandrine, Gondouin, Anne, Dunogué, Bertrand, Chatté, Gérard, Briault, Christophe, Pagnoux, Christian, Jayne, David, Guillevin, Loïc, Cordier, Jean-François·2017·Autoimmunity Reviews
DOI 10.1016/j.autrev.2016.09.018
Open this paper in CoChat — free account

Abstract

Objective To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. Results The study population included 157 patients (mean age 49.4±14.1), with a follow-up of 7.4±6.4years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p=0.005) and with the presence of ANCA (p Conclusion We suggest a revised nomenclature and definition for EGPA and a new proposed entity referred to as hypereosinophilic asthma with systemic (non vasculitic) manifestations.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.autrev.2016.09.018

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Approximately 20% to 50% of patients with hypereosinophilic syndrome exhibit inflammation or fibrosis in the heart.

    “Approximately 20% to 50% of patients with hypereosinophilic syndrome exhibit inflammation or fibrosis in the heart”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [203]

  • Eosinophil-related autoimmune disorders are strongly linked to cardiovascular manifestations including myocarditis.

    “eosinophil-related autoimmune disorders are strongly linked to cardiovascular manifestations including myocarditis.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [203]

  • Over 40% of patients with eosinophilic granulomatosis with polyangiitis experience cardiovascular complications.

    “over 40% of patients with eosinophilic granulomatosis with polyangiitis, also known as ChurgStrauss, experience cardiovascular complications.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [203]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 20

  1. Jennette, 2013, 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Arthritis Rheum, 65, 1, 10.1002/art.37715 · DOI
  2. Churg, 1951, Allergic granulomatosis, allergic angiitis, and periarteritis nodosa, Am J Pathol, 27, 277
  3. Churg, 1995, Formes frustes of Churg-Strauss syndrome, Chest, 108, 320, 10.1378/chest.108.2.320 · DOI
  4. Sinico, 2005, Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome, Arthritis Rheum, 52, 2926, 10.1002/art.21250 · DOI
  5. Sablé-Fourtassou, 2005, Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome, Ann Intern Med, 143, 632, 10.7326/0003-4819-143-9-200511010-00006 · DOI
  6. Healy, 2013, Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome, J Allergy Clin Immunol
  7. Keogh, 2003, Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists, Am J Med, 115, 284, 10.1016/S0002-9343(03)00359-0 · DOI · Paper page
  8. Comarmond, 2013, Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort, Arthritis Rheum, 65, 270, 10.1002/art.37721 · DOI
  9. Cordier, 2013, L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), Presse Med, 42, 507, 10.1016/j.lpm.2013.02.308 · DOI
  10. Sokolowska, 2014, ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center, Clin Exp Rheumatol, 32, S41
  11. Oka, 2011, Two subtypes of Churg-Strauss syndrome with neuropathy: the roles of eosinophils and ANCA, Mod Rheumatol, 21, 290, 10.3109/s10165-010-0400-9 · DOI
  12. Bonatti, 2014, Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art, Front Immunol, 5, 577, 10.3389/fimmu.2014.00577 · DOI
  13. Bochner, 2012, Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD), J Allergy Clin Immunol, 130, 587, 10.1016/j.jaci.2012.07.024 · DOI
  14. Lanham, 1984, Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome, Medicine (Baltimore), 63, 65, 10.1097/00005792-198403000-00001 · DOI
  15. Guillevin, 1996, Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients, Medicine (Baltimore), 75, 17, 10.1097/00005792-199601000-00003 · DOI
  16. Watts, 2007, Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies, Ann Rheum Dis, 66, 222, 10.1136/ard.2006.054593 · DOI
  17. Fokkens, 2005, EAACI position paper on rhinosinusitis and nasal polyps executive summary, Allergy, 60, 583, 10.1111/j.1398-9995.2005.00830.x · DOI
  18. Guillevin, 2011, The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort, Medicine (Baltimore), 90, 19, 10.1097/MD.0b013e318205a4c6 · DOI
  19. Groh, 2015, Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management, Eur J Intern Med, 10.1016/j.ejim.2015.04.022 · DOI · Paper page
  20. Masi, 1990, The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis), Arthritis Rheum, 33, 1094, 10.1002/art.1780330806 · DOI

Cited by

Sorted by citations

Metadata

Authors
Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., Sinico, R. A., Sivasothy, P., Wechsler, M. E., Groh, M., Marchand-Adam, S., Khouatra, C., Wallaert, B., Taillé, C., Delaval, P., Cadranel, J., Bonniaud, P., Prévot, G., Hirschi, S., Gondouin, A., Dunogué, B., Chatté, G., Briault, C., Pagnoux, C., Jayne, D., Guillevin, L., & Cordier, J.-F.
Affiliations
  • Lyon 1 Université (FR)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Azienda Ospedaliera Ospedale Civile di Legnano (IT)
  • University Hospital Schleswig-Holstein (DE)
  • Bicêtre Hospital (FR)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Milano-Bicocca (IT)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • National Jewish Health (US)
  • Hôpital Cochin (FR)
  • Université de Tours (FR)
  • Inserm (FR)
  • Centre Hospitalier Universitaire de Rennes (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Hôpitaux Universitaires de Strasbourg (FR)
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Centre Hospitalier Universitaire de Grenoble (FR)
  • University of Cambridge (GB)
Corresponding author
Cottin, Vincent
ORCID
Venue
Autoimmunity Reviews
Publisher
Elsevier BV
Published
2017-01
Volume
16
Issue
1
Pages
1-9
ISSN
1568-9972 (ISSN-L)
DOI
10.1016/j.autrev.2016.09.018
OpenAlex
W2526725029
Cited by
175
References
0
Citations by year
2026: 13 · 2025: 11 · 2024: 12 · 2023: 18 · 2022: 17 · 2021: 17 · 2020: 25 · 2019: 23 · 2018: 19 · 2017: 18
FWCI
18.18
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Autoimmunity Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
  • Health Sciences › Medicine › Rheumatology › Otitis Media and Relapsing Polychondritis
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
Keywords
eosinophilic granulomatosis with polyangiitis, ANCA, systemic vasculitis, mononeuritis multiplex, eosinophilia, asthma, disease classification, classification criteria, kidney disease, glomerulonephritis, myocarditis
MeSH terms
Adult, Asthma, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prognosis, Retrospective Studies, Churg-Strauss Syndrome, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review